Nielsen O H, Ciardelli T, Wu Z, Langholz E, Kirman I
Department of Medical Gastroenterology C, Herlev Hospital, University of Copenhagen, Denmark, USA.
Am J Gastroenterol. 1995 Aug;90(8):1301-6.
Inflammatory bowel disease is characterized by T cell activation. Activated T cells shed interleukin-2 receptors (IL-2R) in a soluble form. A positive correlation between sIL-2R alpha (CD25) and disease activity in inflammatory bowel disease has been shown previously, whereas IL-2R beta (CD122) has never before been investigated in this respect. Serum from 27 patients with ulcerative colitis (UC), 31 with Crohn's disease (CD), and 29 healthy volunteers was obtained.
Disease activity was scored according to a semiquantitative score for UC and by Crohn's disease activity index for CD. sIL-2R alpha and -beta chains were assessed by a sandwich ELISA technique using monoclonal antibodies specific for CD25 and CD122, respectively.
The median concentration of sIL-2R alpha was 4424 pg/ml in healthy controls, 6460 in UC (p < 0.004), and 6371 in CD (p < 0.01). The corresponding value of sIL-2R beta in healthy volunteers was 605 pg/ml; in active UC, significantly lower levels were found at 233 pg/ml (p < 0.01), whereas in inactive UC, no such difference was observed at 725 pg/ml (p > 0.05). In CD, the levels were 839 pg/ml in inactive and 920 pg/ml in active disease stages (p > 0.05 vs controls). A positive and significant correlation existed between sIL-2R levels of alpha and beta chains in CD (r = 0.64; p < 0.01) but not in UC (r = -0.32; p > 0.05) or in healthy volunteers (r = 0.16; p > 0.05).
Future longitudinal studies will be necessary to learn whether this newly assessed sIL-2R beta (CD122), which may interfere with IL-15R, could be used to predict disease exacerbation and to monitor anti-inflammatory therapy in UC.
炎症性肠病的特征是T细胞活化。活化的T细胞以可溶性形式释放白细胞介素-2受体（IL-2R）。先前已显示可溶性IL-2Rα（CD25）与炎症性肠病的疾病活动之间存在正相关，而IL-2Rβ（CD122）在此方面从未被研究过。获取了27例溃疡性结肠炎（UC）患者、31例克罗恩病（CD）患者和29名健康志愿者的血清。
根据UC的半定量评分和CD的克罗恩病活动指数对疾病活动进行评分。分别使用对CD25和CD122特异的单克隆抗体，通过夹心ELISA技术评估可溶性IL-2Rα和-β链。
健康对照中可溶性IL-2Rα的中位浓度为4424 pg/ml，UC中为6460 pg/ml（p < 0.004），CD中为6371 pg/ml（p < 0.01）。健康志愿者中可溶性IL-2Rβ的相应值为605 pg/ml；在活动期UC中，发现水平显著较低，为233 pg/ml（p < 0.01），而在非活动期UC中，725 pg/ml时未观察到此类差异（p > 0.05）。在CD中，非活动期水平为839 pg/ml，活动期疾病阶段为920 pg/ml（与对照相比，p > 0.05）。CD中α链和β链的可溶性IL-2R水平之间存在显著正相关（r = 0.64；p < 0.01），但UC中不存在（r = -0.32；p > 0.05），健康志愿者中也不存在（r = 0.16；p > 0.05）。
未来有必要进行纵向研究，以了解这种新评估的可能干扰IL-15R的可溶性IL-2Rβ（CD122）是否可用于预测UC疾病加重并监测抗炎治疗。
